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Ionizing radiation-mediated tumor regression de-
pends on type I interferon (IFN) and the adaptive im-
mune response, but several pathways control I IFN
induction. Here, we demonstrate that adaptor pro-
tein STING, but not MyD88, is required for type I
IFN-dependent antitumor effects of radiation. In
dendritic cells (DCs), STING was required for IFN-b
induction in response to irradiated-tumor cells. The
cytosolic DNA sensor cyclic GMP-AMP (cGAMP)
synthase (cGAS) mediated sensing of irradiated-tu-
mor cells in DCs. Moreover, STING was essential
for radiation-induced adaptive immune responses,
which relied on type I IFN signaling on DCs. Exoge-
nous IFN-b treatment rescued the cross-priming
by cGAS or STING-deficient DCs. Accordingly,
activation of STING by a second messenger cGAMP
administration enhanced antitumor immunity in-
duced by radiation. Thus radiation-mediated anti-
tumor immunity in immunogenic tumors requires a
functional cytosolic DNA-sensing pathway and sug-
gests that cGAMP treatment might provide a new
strategy to improve radiotherapy.
INTRODUCTION
Radiotherapy used alone or in combination with surgery or
chemotherapy is employed to treat the primary and metastatic
tumors in approximately 50%–60% of all cancer patients
(Begg et al., 2011; Liauw et al., 2013). The biological responses
of tumors to radiation have been demonstrated to involve DNA
damage, modulation of signal transduction, and alteration of
the inflammatory tumor microenvironments (Begg et al., 2011;
Liauw et al., 2013). Indeed, radiotherapy has been recently
shown to induce antitumor adaptive immunity, leading to tumor
control (Apetoh et al., 2007; Lee et al., 2009). Based on this
concept, the blockade of immune checkpoints improves theIefficacy of radiotherapy on local and distant tumors in experi-
mental systems and more recently in clinical observations
(Deng et al., 2014; Postow et al., 2012). Furthermore, radio-
therapy sculpts innate immune response in a type I interferon
(IFN)-dependent manner to facilitate adaptive immune response
(Burnette et al., 2011). However, the molecular mechanism for
host type I IFN induction following local radiation has not yet
been defined.
The innate immune system is the major contributor to
host-defense in response to pathogen invasion or tissue
damage (Takeuchi and Akira, 2010). The initial sensing of infec-
tion and injury is mediated by pattern-recognition receptors
(PRRs), which recognize pathogen-associated molecular pat-
terns (PAMPs) and damage-associated molecular patterns
(DAMPs) (Chen and Nun˜ez, 2010; Desmet and Ishii, 2012;
Kono and Rock, 2008). The first-identified and well-character-
ized class of PRRs are the Toll-like receptors (TLRs), which
are responsible for detecting PAMPs and DAMPs outside the
cell and in endosomes and lysosomes (O’Neill et al., 2013). Un-
der the stress of chemotherapy and targeted therapies, the
secretion of HMGB-1, which binds to TLR4, has been reported
to contribute to antitumor effects (Apetoh et al., 2007; Park
et al., 2010). However, whether the same mechanism dominates
radiotherapy remains to be determined. Four endosomal TLRs
(TLR3, TLR7, TLR8, and TLR9) that respond to microbial and
host-mislocalized nucleic acids in cytoplasm have more recently
been revealed (Desmet and Ishii, 2012). Through interaction of
the adaptor proteins, myeloid differentiation primary-response
protein 88 (MyD88), and TIR-domain-containing adaptor protein
inducing IFN-b (TRIF), the activation of these four endosomal
TLRs leads to significant induction of type I IFN production (Des-
met and Ishii, 2012; O’Neill et al., 2013). Given that radiation in-
duces production of type I IFNs, it is conceivable that radiation
causes tumor cell nucleic acids and/or stress proteins to trigger
the activation of TLRs and MyD88 and TRIF signaling.
A recently defined endoplasmic-reticulum-associated protein
STING (stimulator of IFN genes) has been demonstrated to be a
mediator for type I IFN induction by intracellular exogenous DNA
in a TLR-independent manner (Burdette and Vance, 2013). Cyto-
solic detection of DNA activates STING in the cytoplasm, which
binds to TANK-binding kinase 1 (TBK1) and IkB kinase (IKK),mmunity 41, 843–852, November 20, 2014 ª2014 Elsevier Inc. 843
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Figure 1. STING Signaling Is Required for the Antitumor Effect of Radiation
MC38 tumors established in WT mice and KO mice were treated locally with one dose of 20 Gy ionizing radiation (IR) or untreated.
(A) 500 mg anti-IFNAR1 was administered intratumorally in WT mice on days 0 and 2 after radiation. Tumor growth was monitored after radiation.
(B) Tumor growth in WT and Myd88/ mice after radiation.
(C) Tumor growth in WT and Trif/ mice after radiation.
(D) 200 mg anti-HMGB1 was administered i.p. in WT mice with tumors on days 0 and 3 after radiation. Tumor growth was monitored after radiation.
(E) Tumor growth in WT and Camp/ mice after radiation.
(F) Tumor growth in WT and Tmem173/ mice after radiation. STING-deficient mice are represented by Tmem173/, whereas CRAMP-deficient mice are
represented by Camp/. Representative data are shown from three (A–F) experiments conducted with 5 (A–D) or 6 to 8 (E and F) mice per group. Data are
represented as mean ± SEM. *p < 0.05, **p < 0.01; ns, no significant difference (Student’s t test). See also Figure S1.
Immunity
STING Drives Radiation-Induced Antitumor Immunitywhich in turn activate the transcription factors IFN regulatory
factor 3 (IRF3), signal transducer and activator of transcription
(STAT6), and nuclear factor-kB (NF-kB), respectively (Paludan
and Bowie, 2013). Subsequently, nuclear translocation of these
transcription factors leads to the induction of type I IFNs and
other cytokines that participate in host defense (Chen et al.,
2011; Paludan and Bowie, 2013). In the past 6 years, STING
has been demonstrated to be essential for the host protection
against DNA pathogens through various mechanisms (Chen
et al., 2011; Ishikawa and Barber, 2008; Ishikawa et al., 2009).
STING is also a mediator for autoimmune diseases, which are
initiated by the aberrant cytoplasmic DNA (Ahn et al., 2012;
Gall et al., 2012; Gehrke et al., 2013). Following the recognition
of cytosolic DNA, cGAMP synthase (cGAS) catalyzes the gener-
ation of 20 to 50 cyclic GMP-AMP (cGAMP), which binds to and
activates STING signaling (Li et al., 2013; Sun et al., 2013; Wu
and Chen, 2014; Wu et al., 2013). More recently, cGAS has
been considered as a universal cytosol DNA sensor for STING
activation, such as in the setting of viral infection and lupus ery-
thematosus (Gao et al., 2013a; Gehrke et al., 2013; Lahaye et al.,
2013; Liang et al., 2013). On the basis of these considerations, it
has become important to determine whether innate immune
sensing following tumor radiation is mediated through TLR path-
ways or the alternative STING pathway.844 Immunity 41, 843–852, November 20, 2014 ª2014 Elsevier Inc.Here, we demonstrate that innate immune sensing following
radiotherapy is dominated by the cGAS-STING-dependent cyto-
solic DNA sensing pathway, which drives the adaptive immune
response to radiation. Our study provides insight through better
understanding of the mechanism of radiation-mediated tumor
regression and forms the basis for new strategies to improve
radiotherapy efficacy in cancer patients.
RESULTS
STING Signaling Mediates Antitumor Effects of
Radiation
We previously demonstrated that antitumor effects of radiation
were dependent on type I IFN signaling by utilizing IFNAR1-defi-
cient mice (Burnette et al., 2011). To rule out the possibility that
the failure of tumors to respond to radiation was due to the
intrinsic or developmental deficiency of IFNAR1-deficient mice,
we administered blocking antibody against IFNAR1 in wild-
type (WT) mice following radiation. The results were similar to
the effects observed in the knockout (KO) mice in that the anti-
tumor effect of radiation was greatly attenuated by the neutrali-
zation of type I IFN signaling with antibodies (Figure 1A). It has
been demonstrated that MyD88 is essential for antitumor immu-
nity of chemotherapy and targeted therapy with anti-HER2
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Figure 2. STING Signaling Is Essential for
IFN-b Induction by Radiation
(A and B) Tumors were excised on day 3 after ra-
diation and homogenized in PBS with protease
inhibitor. After homogenization, Triton X-100 was
added to obtain lysates. ELISA assay was per-
formed to measure IFN-b (A) and CXCL10 (B).
(C) 72 hr after radiation, single cell suspensions
from tumors in WT and Tmem173/ mice were
stained with 7-AAD and conjugated antibodies
against CD45, CD11c, and CD11b, and then sor-
ted into different cell populations by flow cy-
tometry. IFN-bmRNA in different cell subsets was
quantified by real-time PCR assay. STING-defi-
cient mice are represented by Tmem173/.
Representative data are shown from three exper-
iments conducted with four mice per group. Data
are represented as mean ± SEM. *p < 0.05, **p <
0.01 and ***p < 0.001 (Student’s t test). See also
Figure S2.
Immunity
STING Drives Radiation-Induced Antitumor Immunity(Apetoh et al., 2007; Park et al., 2010; Stagg et al., 2011). To
investigate whether MyD88 is required to mediate response to
radiation therapy, we implanted tumor cells on flanks of WT
and MyD88-deficient mice. The inhibition of tumor growth post-
radiation was comparable between WT and MyD88-deficient
mice (Figure 1B), demonstrating that host MyD88 was dispens-
able for the antitumor effect of radiation. To examine whether
TRIF might be involved in the antitumor effects of radiation, we
implanted tumor cells intoWT and TRIF-deficient mice. Absence
of host TRIF also failed to prevent the antitumor activity of radi-
ation (Figure 1C), consistent with previous data (Burnette et al.,
2011). Similar to chemotherapy and targeted antibody therapies,
radiotherapy induces cell stress and results in the secretion of
DAMPs. Next, we examined whether HMGB-1 secretion might
be involved in the antitumor effect of radiation. We blocked
HMGB-1 by administering specific antibodies along with radia-
tion. However, tumor control by radiation was unaffected by
anti-HMGB-1 treatment (Figure 1D), suggesting that HMGB-1
secretion is also not required for the antitumor effect of radiation.
The cathelicidin-related antimicrobial peptide (CRAMP in mice
and LL37 in human) has been identified as a mediator of type I
IFN induction by binding self-DNA to trigger the TLR9-MyD88
pathway (Diana et al., 2013; Lande et al., 2007). To test the pos-
sibility that CRAMP might be responsible for the radiation
response, we inoculated tumor cells into WT and CRAMP-defi-
cient mice (CRAMP is encoded by Camp). Absence of host
CRAMP also failed to prevent the antitumor effect of radiation
(Figure 1E). Taken together, these data indicate that well-char-
acterized TLR-dependent molecular mechanisms involved in
chemotherapy and targeted antibody therapies are not respon-
sible for the antitumor efficacy of radiation. Also, these resultsImmunity 41, 843–852, Nraise the possibility that a unique molecu-
lar mechanism that is TLR-independent
for type I IFN induction mediates the anti-
tumor effect of radiation.
Recently, the STING-mediated cyto-
solic DNA sensing cascade has been
demonstrated to be a major mechanism
of TLR-independent type I IFN induction.To determine the role of STING in the radiation response, we im-
planted tumor cells on flanks of WT and STING-deficient mice
(STING is encoded by Tmem 173) and monitored tumor growth.
We found that, while tumor burden was significantly reduced by
radiation in WT mice, absence of host STING significantly
impaired the antitumor effect of radiation (Figure 1F), demon-
strating that STING signaling is essential for the maximal anti-
tumor effect of radiation. The antitumor effects of radiation
were also impaired in STING-deficient mice when two doses of
radiation treatment were utilized (see Figure S1 available online).
Taken together, these results suggest that the STING-depen-
dent cytosolic DNA sensing pathway is critical for the therapeutic
effect of radiation in vivo.
STING Signaling Controls Type I IFN Induction and
Innate Immune Responses upon Radiation
To test whether STING was responsible for type I IFN induction
following radiation, we measured the amount of IFN-b protein
in tumors. The induction of IFN-b in tumors was significantly
abrogated in the absence of STING in the host after radiation
(Figure 2A). As further confirmation, we found that the amount
of CXCL10, a type I IFN-stimulated gene (Ablasser et al., 2013;
Holm et al., 2012), was also markedly diminished in tumors after
radiation in STING-deficient hosts (Figure 2B). These results
indicate that host STING is required for type I IFN induction by
radiation. Next, to determine in which cell population STINGme-
diates type I IFN induction, we performed quantitative real-time
PCR assay of IFN-b in different sorted cell populations isolated
from tumors after radiation. The phenotype of CD11c+ cells in tu-
mors was characterized (Figure S2A). We observed that CD11c+
DCs were the major producer of IFN-b after radiation, comparedovember 20, 2014 ª2014 Elsevier Inc. 845
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Figure 3. STING-IRF3 Axis in DCs Is Acti-
vated by Irradiated-Tumor Cells
(A–C) BMDCs were cultured with 40 Gy-pretreated
MC38-SIY cells or nonirradiated-MC38-SIY cells.
Subsequently purified CD11c+ cells were cocul-
tured with isolated CD8+ T cells from naive 2Cmice
for 3 days and analyzed by ELISPOT assays. (A)
BMDCs from WT or Tmem173/ mice were used
for coculture with irradiated or nonirradiated MC38-
SIYcells.DCcross-primingactivitywasanalyzedby
ELISPOT assays. (B) BMDCs from WT or Irf3/
mice were used for coculture with irradiated or
nonirradiated MC38-SIY cells. DC cross-priming
activity was analyzed by ELISPOT assays. (C) WT
and Tmem173/ BMDCs were cultured with 40
Gy-pretreatedMC38-SIYhi cells. 10ng/ml IFN-bwas
added into thecocultureofTmem173/BMDCand
irradiated-MC38-SIY cells. 100 mg/ml DMXAA was
added to isolated Tmem173/ CD11c+ cells for
additional 3 hr incubation. DCcross-priming activity
was analyzed by ELISPOT assays.
(D) WT and Tmem173/ BMDCs were cocultured
with 40Gy-pretreatedMC38-SIY cells. The purified
CD11c+ cells were incubated for additional 2 days
and the supernatants were collected to measure
IFN-b by ELISA assay. STING-deficient mice are
represented by Tmem173/. Representative data
are shown from three (A–D) experiments. Data are
represented as mean ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001; ns, no significant difference (Student’s
t test). See also Figures S2 and S3.
Immunity
STING Drives Radiation-Induced Antitumor Immunityto the CD45 population and the rest of myeloid cells (Figure 2C).
In contrast, radiation-mediated induction of IFN-bmRNA by DCs
was abolished in STING-deficient hosts (Figure 2C). Together,
these data suggest that host STING controls radiation-mediated
type I IFN induction in tumors and that the presence of STING in
tumor-infiltrating DCs plays a major role in type I IFN induction
after radiation.
To determine whether STING signaling is activated by irradi-
ated-tumor cells and whether it is essential for DC-mediated
cross-priming of CD8+ T cells, a cross-priming assay was con-
ducted with BMDCs from WT and STING-deficient mice. The
phenotype of CD11c+ cells from GM-CSF stimulated bone
marrow cells was characterized (Figure S2B). The functional
capability of DCs to cross-present antigen was augmented by
the stimulation of irradiated-tumor cells compared to nonir-
radiated-tumor cells, whereas the deficiency of STING in DCs
resulted in failed responses of DCs to cross-prime T cells (Fig-
ure 3A). In contrast, CD19+ B cells isolated from the spleen of
naive mice were unable to cross prime T cells (Figure S3A). To
determine whether DCs differentiated in vivo were also function-
ally affected by STING, we isolated CD11c+ cells from the spleen
of WT and STING-deficient mice to perform cross-priming
assays. Similar to in vitro generated DCs, splenic DCs were
impaired in the absence of STING (Figure S3B). To confirm
whether IRF3 is essential to the function of DCs by the stimula-
tion of irradiated-tumor cells, we performed cross-priming assay
with WT BMDCs and IRF3-deficient BMDCs. Similar to STING-
deficient BMDCs, IRF3-deficient BMDCs failed to cross-prime
CD8+ T cells in response to stimulation with irradiated-tumor
cells (Figure 3B). These results indicate that the STING-IRF3846 Immunity 41, 843–852, November 20, 2014 ª2014 Elsevier Inc.axis in DCs is activated by irradiated-tumor cells and is the
predominant innate signaling pathway needed for cross-priming
by DCs.
To determine whether exogenous IFN-b treatment rescues the
functions of STING-deficient BMDCs, we added IFN-b to cocul-
tured BMDCs and irradiated-tumor cells. The ability of STING-
deficient BMDCs to cross-prime specific T cells was restored
in the presence of exogenous IFN-b treatment (Figure 3C).
Recently, it has been demonstrated that DMXAA, a small
molecule inducing cytokine production and disrupting tumor
vascularization, binds to murine STING and activates STING
signaling to induce type I IFN production (Gao et al., 2013b).
DMXAA failed to rescue the function of STING-deficient BMDCs;
confirming activation of STING is required to increase cross-
priming through IFN pathway (Figure 3C). Next, to rule out the
possibility that the impaired capacity of STING-deficient DCs
and IRF3-deficient DCs for priming is due to intrinsic defects of
these cells, a direct priming assay was performed with peptide
stimulation. No difference was observed between WT BMDCs
and STING-deficient BMDC function in priming 2C cells with
the stimulation of SIY peptide (Figure S3C). This result suggests
that STING-deficient DCs do not have an intrinsic defect in direct
priming of T cells. IRF3-deficient DCs also retained the ability to
directly prime 2C T cells with SIY peptide stimulation (Fig-
ure S3C). To determine whether STING signaling might be
activated by irradiated-tumor cells, we assessed the production
of IFN-b by WT and STING-deficient BMDCs stimulated by irra-
diated-tumor cells. While the amount of IFN-b induction in
response to irradiated-tumor cells was less than that induced
by STING pathway agonists such as DMXAA (data not shown),
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B Figure 4. cGAS Is Essential for DC Sensing
of Irradiated-Tumor Cells
(A–C) BMDCs were cultured with 40 Gy-pre-
treated MC38-SIY or nonirradiated-MC38-SIY
cells. Subsequently purified CD11c+ cells were
cocultured with isolated CD8+ T cells from
naive 2C mice for 3 days. (A) BMDCs from WT
and Mb21d1/ mice were used for coculture
with irradiated and nonirradiated MC38-SIY
cells. DC cross-priming activity was analyzed
by ELISPOT assays. (B) BMDCs were trans-
fected with a siRNA-nontargeting control or
siRNA-Mb21d1. Two days later after the
transfection, the BMDCs were harvested for the
coculture with irradiated and nonirradiated
MC38-SIY cells. DC cross-priming activity was
analyzed by ELISPOT assays. (C) WT and
Mb21d1/ BMDCs were cultured with 40 Gy-
pretreated MC38-SIY cells. 10 ng/ml IFN-b was
added into the coculture of Mb21d1/ BMDC
and irradiated-MC38-SIY cells. 100 mg/ml
DMXAA was added to isolated Mb21d1/
CD11c+ cells for additional 3 hr incubation.
DC cross-priming activity was analyzed by
ELISPOT assays.
(D) CD11c+ cells fromWT orMb21d1/BMDCs after coculture with irradiated or nonirradiated MC38-SIY cells were incubated for 2 days, and then subjected to
ELISA assays for IFN-b level.
(E) CD11c+ cells were sorted from tumors in WT mice at 72 hr after radiation. Real-time PCR assay was performed to quantify the Mb21d1 mRNA. cGAS-
deficient mice are represented by Mb21d1/. Representative data are shown from three (A–E) experiments. Data are represented as mean ± SEM. **p < 0.01
and ***p < 0.001 (Student’s t test). See also Figure S4.
Immunity
STING Drives Radiation-Induced Antitumor Immunitywe were nonetheless able to characterize the molecular require-
ments for this induction. The amount of IFN-b induced by irradi-
ated-tumor cells (MC38) in vitro was reduced in STING-deficient
BMDCs compared to WT BMDCs (Figure 3D). A similar differ-
ence was also observed when WT and STING-deficient BMDCs
were stimulated by another tumor cell line (B16) in vitro (Fig-
ure S3D). These results suggest that activation of STING by irra-
diated-tumor cells controls type I IFN induction in DCs and that
this process is crucial for the ability of DCs to cross-prime
CD8+ T cells. These results also raise the possibility that STING
molecules in DCs are stimulated by a component provided by
irradiated-tumor cells, presumably DNA.
cGAS Mediates DC Sensing of Irradiated-Tumor Cells
To interrogate whether cGAS (encoded by Mb21d1) is required
for DC sensing of irradiated-tumor cells to stimulate adaptive im-
munity, we compared the function of BMDCs from WT and
cGAS-deficient mice. In contrast to WT BMDCs, cGAS-deficient
BMDCs failed to cross-prime 2C cells in response to stimulation
by irradiated-tumor cells (Figure 4A). To validate that the pheno-
type of cGAS-deficient BMDCs is not due to intrinsic or develop-
mental defects, we silenced cGAS in WT BMDCs using siRNA.
The silencing of cGAS in BMDCs diminished cross-priming
by DCs compared to the silencing of nontarget controls, when
stimulated with irradiated-tumor cells (Figure 4B). The results
confirmed that cGAS is essential for sensing of irradiated-tumor
cells by DCs. Tomapwhether the cGAS-STING-type I IFN axis is
needed for cross-priming by BMDCs, we performed bypass
experiments in which either DCs were cocultured with irradi-
ated-tumor cells in the presence of exogenous IFN-b or isolated
DCs from the coculture were additionally stimulated withIDMAXX. The cross-priming by cGAS-deficient BMDCs were
restored with IFN-b and DMXAA treatment, respectively (Fig-
ure 4C). To further assess whether cGAS is required for sensing
of irradiated-tumor cells by BMDC, we determined the produc-
tion of IFN-b byWT BMDCs and by cGAS-deficient BMDCs after
stimulation with irradiated-tumor cells. Indeed, the amount of
IFN-b induced by irradiated-tumor cells was decreased in
cGAS-deficient BMDCs compared to WT BMDCs (Figure 4D).
Mb21d1 mRNA was detected in CD11c+ cells from tumors and
increased after radiation in vivo (Figure 4E). We also performed
the cross-priming assay using irradiated-human tumor cells ex-
pressing SIY and again found the cross-priming by DCs was
impaired in the absence of STING or cGAS (Figure S4A). Thus
cGAS responds to irradiated-murine and -human tumor cells
and initiates type I IFN production to enhance DC cross-priming
activity.
The results suggest that DNA from irradiated-tumor cells
might gain access to the cytosolic DNA sensing pathway to
trigger STING-dependent type I IFN induction. DNA from irradi-
ated-tumor cells could be delivered into the cytosol of DCs as
free DNA or as membrane-associated DNA transferred by
membrane fusion. The priming ability of DCs in response to irra-
diated-tumor cells was not impaired by the presence of DNase I
(Figure S4B), suggesting that DCs do not engulf free DNA frag-
ments. To test whether DNA delivery is contact-dependent,
BMDCs were separated from irradiated-tumor cells via a trans-
well screen that only allows particles under 0.4 mm in diameter
to travel freely between compartments. Under these settings,
DC cross-priming activity was abolished (Figure S4C), indicating
that DNA delivery is mediated by direct cell-cell contact. Further-
more, the addition of Latrunculin B, an actin polymerizationmmunity 41, 843–852, November 20, 2014 ª2014 Elsevier Inc. 847
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Figure 5. STING Signaling Is Required for Effective Adaptive Immune Responses Mediated by Type I IFN Signaling on DCs after Radiation
MC38 tumors established in WT, Tmem173/, Cd11cCre+ Ifnarf/f, and Ifnarf/f mice were treated locally with one dose of 20 Gy.
(A) 300 mg anti-CD8 mAb was administered i.p. in WT mice every 3 days for a total of four times starting from the day of radiation. Tumor growth was monitored.
(B) Eight days after radiation, tumor draining inguinal lymph nodes (DLNs) were removed from WT and Tmem173/ mice. Tumor antigen-specific CD8+ T cell
function was measured by ELISPOT assays by coculturing purified CD8+ cells with IFN-g-treated MC38 tumor cells.
(C) 1 3 1010 viral particles of Ad null or Ad-IFN-b were administered intratumorally on day 2 after radiation. Tumor DLNs were removed on day 8 after radiation.
Isolated CD8+ cells were subjected to ELISPOT assay with the presence of IFN-g-treated MC38 tumor cells.
(D) Tumor growth curves were analyzed in Cd11cCre+ Ifnarf/f and Ifnarf/f mice after radiation.
(E) Tumor DLNs fromCd11cCre+ Ifnarf/f and Ifnarf/f mice were removed on day 8 after radiation. ELISPOT assays were performed with purified CD8+ cells and IFN-
g-treated MC38 tumor cells. STING-deficient mice are represented by Tmem173/. Representative data are shown from three (A–E) experiments conducted
with 5–6 (A and D) or 3–4 (B, C, and E) mice per group. Data are represented as mean ± SEM. **p < 0.01 and ***p < 0.001 (Student’s t test). See also Figure S5.
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STING Drives Radiation-Induced Antitumor Immunityinhibitor, in the coculture led to a dramatic reduction in the ability
of DCs to induce cross-priming (Figure S4D). Production of IFN-b
by DCs in response to irradiated-tumor cells was also greatly
decreased by application of a physical barrier or an actin poly-
merization inhibitor (Figure S4E). Taken together, these results
suggest that DNA from irradiated-tumor cells is sensed by host
cGAS during a cell-cell contact-mediated process.
STING Signaling Promotes Adaptive Immune Responses
upon Radiation
Our previous studies have shown that adaptive immune re-
sponses play a role in the antitumor effect of radiation alone or
combined with immunotherapy (Deng et al., 2014; Lee et al.,
2009; Liang et al., 2013). To validate the role of CD8+ T cells after
radiation in the MC38 tumor model, depleting antibodies against
CD8+ T cells were administrated after radiation, and in agree-
ment with our previous reports, the antitumor effect of radiation
was reduced (Figure 5A) similar to the tumor growth curve in
STING-deficient mice after radiation. To examine whether the
failure of STING-deficient mice to respond to radiation is due
to impaired CD8+ T cell function, we performed an ELISPOT
assay with purified CD8+ T cells from tumor inguinal draining848 Immunity 41, 843–852, November 20, 2014 ª2014 Elsevier Inc.lymph nodes (DLNs). Radiation induced robust tumor antigen-
specific CD8+ T cell responses in WT mice, whereas the anti-
gen-specific CD8+ T cell responses in STING-deficientmice after
radiation were diminished (Figure 5B). CD8+ T cells purified from
mice that received radiation were reactivated with MC38 cells,
but not B16F10 cells, confirming the assay detects tumor-spe-
cific T cell responses (Figure S5). To determine whether impaired
CD8+ T cell responses in STING-deficient mice postradiation
were due to the insufficient induction of type I IFNs, STING-defi-
cient mice received intratumoral treatment with Adenovirus
(Ad)-IFN-b after radiation. Exogenous IFN-b treatment was
able to restore the CD8+ T cell function in STING-deficient
mice after radiation (Figure 5C). The CD8+ T cell response in
STING-deficient and WT mice was demonstrated previously to
be equivalent (Ishikawa et al., 2009). These data show reduced
production of type I IFNs rather than intrinsic defects in CD8+
T cells accounts for impaired adaptive immunity in STING-defi-
cient mice after radiation.
To further determine whether DCs are directly responsible for
type I IFN signaling after radiation, we implanted tumor cells into
Cd11cCre+-Ifnar1f/f mice and Ifnar1f/f mice. Conditional deletion
of Ifnar1 in DCs hampered the antitumor effect of radiation
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STING Drives Radiation-Induced Antitumor Immunity(Figure 5D), demonstrating that type I IFN signaling on DCs are
responsible for antitumor effects of radiation. CD8+ T cell func-
tion in the DLNs after irradiation was compromised inCd11cCre+-
Ifnar1f/f mice versus Ifnar1f/f mice after radiation (Figure 5E).
These results indicate that type I IFN signaling on DCs is required
for antitumor efficacy of radiation by boosting adaptive immune
responses.
cGAMPTreatment andRadiation Synergistically Amplify
the Antitumor Immune Response
It has been demonstrated that 2030-cGAMP (cyclic [G(20,50)
pA(30,50)p]) is generated inmammalian cells by cGAS in response
to double-stranded DNA in the cytoplasm (Gao et al., 2013a; Wu
et al., 2013; Zhang et al., 2013). We hypothesized that exoge-
nous 2030-cGAMP treatment might improve the antitumor effect
of radiation by enhancing STING activation. To test this hypoth-
esis, we intratumorally administrated 2030-cGAMP after radia-
tion. Treatment with a combination of 2030-cGAMP and radiation
more effectively reduced tumor burden compared to 2030-
cGAMP or radiation alone in WT mice, suggesting that cGAMP
treatment can potentiate the effect of radiation (Figure 6A). In
addition, about 70% of mice completely rejected the tumors at
the completion of combination treatment (Figure 6B). In contrast,
the synergy of 2030-cGAMP and radiation was abrogated in
STING-deficient mice (Figures 6A and 6B). Together, these
data indicate that boosting activation of STING signaling
is able to inhibit tumor growth after radiation. To address
whether the combination of 2030-cGAMP and radiation enhanced
tumor-specific T cell responses, we performed ELISPOT assays
with isolated CD8+ T cells from DLNs, cocultured with IFN-g-
treated MC38. The number of tumor-specific IFN-g-producing
CD8+ T cells was increased in DLNs of mice that received com-
bination treatment compared with those that received radiationIor 2030-cGAMP alone (Figure 6C). However, the robust antitumor
CD8+ T cell response induced by the combination of 2030-cGAMP
and radiation was dampened in STING-deficient hosts (Fig-
ure 6D). Together, these results indicate that 2030-cGAMP treat-
ment potentiates the therapeutic effect of radiation by further
enhancing tumor-specific CD8+ T cell functions and that the syn-
ergy is dependent on the presence of STING in the host.
DISCUSSION
Radiation has been demonstrated to induce adaptive immune
responses to support tumor regression (Apetoh et al., 2007;
Lee et al., 2009). The induction of type I IFNs by radiation is
essential for the function of CD8+ T cells (Burnette et al., 2011).
Although the importance of type I IFNs has been elucidated us-
ing mice lacking IFNAR1 in all tissues, the identity of the immune
cells that are responsible for type I IFN responses after radiation
has been unclear. In addition, because of the diverse range of
stimuli able to generate type I IFN production, it is necessary
to discern the mechanism responsible for type I IFN induction
by radiation in order to develop potential therapeutics that target
this pathway. Various nucleic acid-sensing pathways from
different subcellular compartments have been reported to play
a critical role in inducing type I IFNs in response to pathogen
infection and tissue injury (Desmet and Ishii, 2012; Wu and
Chen, 2014). Indeed, radiation induces cell stress and causes
excess DNA breaks, indicating that nucleic acid-sensing path-
ways could feasibly account for the induction of type I IFNs
upon radiation. We identified that the cGAS- and STING-depen-
dent cytosolic DNA sensing pathway in DCs is required for type I
IFN induction after radiation, and that type I IFN signaling on DCs
determines the radiation-mediated adaptive immune responses.
In addition, enhancing STING signaling by exogenous cGAMPmmunity 41, 843–852, November 20, 2014 ª2014 Elsevier Inc. 849
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STING Drives Radiation-Induced Antitumor Immunitytreatment facilitated the antitumor effect of radiation. Therefore,
the STING pathway is a key mediator of tumor immune re-
sponses to therapeutic radiation (Figure S6).
We found that, while type I IFN responses in DCs dictated the
efficacy of antitumor radiation, no evidence for involvement of
HMGB-1 release or MyD88 signaling was detected. In contrast,
chemotherapeutic agents and anti-HER2 antibody treatments
have previously been demonstrated to depend on a distinct
immune mechanism to trigger adaptive immune responses
(Apetoh et al., 2007; Park et al., 2010). Anti-HER2 treatment
and chemotherapy require HMGB-1 release from dying tumor
cells, as well as TLR4 and its adaptor MyD88 on DCs. The inter-
action of HMGB-1 and TLR4 potentiates the processing of dying
tumor cells by DCs, leading to efficient cross-priming of CD8+
T cells. However, the antitumor effects of some chemotherapy
agents have been shown to depend on MyD88 signaling, but
not TLR4 (Iida et al., 2013). Although MyD88 signaling has
been shown to be necessary for responses to vaccination with
irradiated-tumor cells, it was unanticipated that this signaling
pathway is dispensable for radiation treatment of established
tumors. Nevertheless, our study demonstrates that the induction
of type I IFNs by radiation depends on STING pathway signaling,
validating that this particular molecular mechanism mediates
antitumor immune responses to radiation.
The cGAS-STING pathway is a key component for activation
of innate immune response to DNA from various pathogens,
including viruses, bacteria, and parasites (Gao et al., 2013a; La-
haye et al., 2013; Liang et al., 2013; Lippmann et al., 2011;
Sharma et al., 2011). In addition to pathogens, the cGAS-STING
signaling pathway might play a dominant role in response to
transfected DNA. Two groups have linked this signaling with
DNA vaccines performed by intramuscular electroporation. One
report found that TBK1 mediates antigen-specific B cell and
T cell immune responses after DNA vaccination through type I
IFN induction (Ishii et al., 2008). Another report pointed out that
STING is essential for DNA vaccine-induced adaptive immune
responses (Ishikawa et al., 2009). The release of DNA from dying
host cells has been shown to stimulate adaptive immune re-
sponses in theTBK1-IRF3-type I IFN-dependentmanner, leading
to alum adjuvant activity (Marichal et al., 2011). In addition,
oxidized self-DNA released from dying cells has been demon-
strated to activate the cGAS-STING pathway as a mechanism
to sense UV-exposed skin lesions (Bernard et al., 2012). Our re-
sults have revealed that the cGAS-STING-dependent cytosolic
DNA sensing pathway mediates the efficacy of therapeutic radi-
ation. It is likely that DNA derived from irradiated-tumor cells is a
mediator of cGAS-STING signaling in DCs in vivo.
How DNA from irradiated-tumor cells is delivered into the
cytosol of DCs remains unknown. DNA binding proteins such
as LL37 are prevalent in neutrophil extracellular traps (NETs)
and believed to enhance cytoplasmic delivery of DNA (Diana
et al., 2013; Lande et al., 2007). Indeed, several reports have
shown that STING signaling is activated by a DNA-LL37 complex
(Chamilos et al., 2012; Gehrke et al., 2013). However, we have
not been able to find that DNA is delivered either by free floating
form or by complex forms. It is therefore possible that DNA from
irradiated-tumor cells is delivered into the cytosol of DCs during
a cell-cell contact process. Moreover, radiation is able to induce
tumor cells and phagocytes to generate reactive oxygen species850 Immunity 41, 843–852, November 20, 2014 ª2014 Elsevier Inc.(ROS), and then oxidated DNA modified by ROS is resistant to
cytosolic exonuclease TREX-1-mediated degradation (Gehrke
et al., 2013; Moeller et al., 2004). It is conceivable that radia-
tion-induced ROS maintains the stability of tumor cell DNA dur-
ing delivery into the cytosol of DCs. Elucidating the mechanism
by which tumor-derived DNA finds access to the cytosol of
host DCs in vivo will be of interest to carry out in future studies.
Our study not only reveals a previously unknown mechanism
by which cytosolic DNA-cGAS-STING pathway controls radia-
tion-mediated antitumor immunity but also indicates that the
combination of radiation and the STING agonist cGAMP reduces
radioresistence and synergistically increases the antitumor host
response. Although the free-radical generation involved in DNA
damage upon irradiation is short, the multiple integral events
(especially in the microenvironment) generated by radiation
can persist over longer time periods (3–10 days). The compo-
nents of immune responses to radiation include release of
danger signals, recruitment of myeloid cells, modulation of signal
transduction, and alteration of innate and adaptive immune
responses. It is likely that the activation of STING signaling by
radiation occurs in newly replenished myeloid cells with high
cross-priming activity, whereas the activation of STING by
cGAMP alone occurs in the tolerized immune cells with low
cross-priming activity. In addition, delivery of cGAMP into the
cytosol from injection might not be very effective, and retention
of cGAMP by injection could be much shorter than sustained
release of DNA over periods of days induced by radiation. It is
therefore conceivable that the antitumor effects of radiation are
unable to be reproduced by treatment of cGAMP alone. Whether
radiation also promotes the delivery of cGAMP remains to be
determined.
In summary, we demonstrate that the adaptor protein STING,
and not MyD88 or TRIF, is required for the antitumor effect of
radiation and the induction of type I IFNs. This mechanism ap-
pears to involve cGAS for sensing of DNA by DCs in response
to irradiated-tumor cells. The cGAS-STING-IRF3-Type I IFN
cascade mediates a robust adaptive immune response to radia-
tion. In addition, exogenous cGAMP treatment synergizes with
radiation to control tumors. Therefore, our findings reveal a mo-
lecular mechanism of radiation-mediated antitumor immunity
and highlight the potential to improve radiotherapy by cGAMP
administration.
EXPERIMENTAL PROCEDURES
Mice
Six- to eight-week old C57BL/6J mice were purchased from Harlan.
Myd88/, Trif/, Camp/, 2C CD8+ T cell receptor (TCR)-Tg, Cd11cCre+-
Tg mice were purchased from The Jackson Laboratory. Ifnar1flox/flox mice
were kindly provided by Dr. Ulrich Kalinke of the Institute for Experimental
Infection Research. Tmem173/ mice were kindly provided by Dr. Glen N.
Barber of University of Miami School of Medicine. Irf3/mice were kindly pro-
vided by T. Taniguchi of University of Tokyo. All the mice were maintained un-
der specific pathogen-free conditions and used in accordance to the animal
experimental guidelines set by the Institute of Animal Care and Use Commit-
tee. This study has been approved by the Institutional Animal Care and Use
Committee of the University of Chicago.
Tumor Growth and Treatments
13 106 MC38 tumor cells were subcutaneously injected into the flank of mice.
Tumors were measured and irradiated at 20 Gy or 2 3 15 Gy as described in
Immunity
STING Drives Radiation-Induced Antitumor Immunity(Deng et al., 2014). For type I IFN blockade experiments, 200 mg anti-IFAR1
mAb was intratumorally injected on day 0 and 2 after radiation. For HMGB-1
blockade experiments, 200 mg anti-HMGB-1 mAb was administered intraper-
itoneally (i.p.) on day 0 and 3 after radiation. For CD8+ T cell depletion exper-
iments, 300 mg anti-CD8 mAb was delivered 5 times by i.p. injection every
3 days starting 1 day before radiation. For exogenous IFN-b treatment exper-
iments, 1 3 1010 viral particles of Adenovirus (Ad) -IFN-b were intratumorally
administered on day 2 after radiation. Ad null was used as negative control.
For cGAMP treatment experiments, 10 mg 2030-cGAMP in PBSwas intratumor-
ally administered on days 2 and 6 after radiation.
In Vitro Culture and Function Assay of BMDCs
Single-cell suspensions of bone marrow cells were obtained from C57BL/6J,
Tmem173/, and Irf3/ mice. Bone marrow from Mb21d1/ mice was
kindly provided by Dr. Zhijian J. Chen of University of Texas Southwestern
Medical Center, Dallas (Li et al., 2013). The cells were placed in 10 cm petri
dish and cultured in RPMI-1640 medium containing 10% FBS (DENVILLE),
supplemented with 20 ng/ml GM-CSF. Fresh media with GM-CSF was added
into culture on day 3. BMDCs were harvested for stimulation assay on day 7.
83 106 MC38-SIYhi cells were plated into 10 cm cell culture dishes overnight,
and then pretreated with 40 Gy and incubated for 5 hr. BMDCs were added
and cocultured withMC38-SIYhi cells at the ratio of 1:1 in the presence of fresh
GM-CSF for an additional 6–8 hr. Subsequently purified CD11c+ cells with
EasySep Mouse CD11c Positive Selection Kit II (STEMCELL) were incubated
with isolated CD8+ T cells from naive 2C mice for 3 days. For the bypassing
assay, 10 ng/ml murine IFN-bwas added in the coculture of BMDCs and tumor
cells, or 100 mg/ml DMXAA was added into isolated CD11c+ cells with addi-
tional 3 hr incubation prior to coculture with CD8+ T cells. For IFN-b detection,
13 106 cells/ml purified CD11c+ cells from coculture were seeded into 96-well
plates and the supernatants were harvested after 2 day incubation.
ELISA
Tumor tissues were excised on day 3 after radiation and homogenized in PBS
with protease inhibitor. After homogenization, Triton X-100 was added to
obtain lysates. Cell culture supernatants were obtained from isolated
CD11c+ cells after 48 hr-incubation with fresh GM-CSF. The concentration
of IFN-b and CXCL10 was measured with VeriKine-HS Mouse Interferon
Beta Serum ELISA Kit (PBL Assay Science) and mouse CXCL10 Quantikine
ELISA kit (R&D) in accordance with the manufacturer’s instructions,
respectively.
Measurement of IFNg-Secreting CD8+ T Cells by ELISPOT Assay
For bone-marrowCD11c+ cells functional assay, 23 104 purified CD11c+ cells
were incubated with isolated CD8+ T cells from naive 2C mice with EasySep
Mouse CD8a Positive Selection Kit (STEMCELL) for 3 days at the ratio of
1:10. For tumor-specific CD8+ T cells functional assay, 8 days after radiation,
tumor DLNs were removed and CD8+ T cells were purified. MC38 tumor cells
were exposed to 20 ng/ml murine IFN-g for 24 hr prior to plating with purified
CD8+ T. 23 105 CD8+ T cells were incubated with MC38 at the ratio of 10:1 for
48 hr. ELISPOT assays were performed to detect the cytokine spots of IFN-g
according to product protocol (Millipore).
RNA Interference
siRNAs (Mission siRNA) against murine cGAS and control siRNA were pur-
chased from Sigma as described. BMDCswere transfectedwith siRNA by Lip-
ofectamine RNAiMAX Reagent (Invitrogen) at a final concentration of 50 nM:
mmcGAS 50-GAGGAAAUCCGCUGAGUCAdTdT-30 (Ablasser et al., 2013);
Mission siRNA Universal Negative control 1. Forty-eight hours after transfec-
tion, cells were used for further experiments.
RNA Extraction and Quantitative Real-Time PCR
Total RNA from sorted cells was extracted with the RNeasyMicro Kit (QIAGEN)
and reversed-transcribed with Seniscript Reverse Transcription Kit (QIAGEN).
Real-time PCR was performed with SSoFast EvaGreen supermix (Bio-Rad)
according to the manufacturer’s instructions and different primer sets on Ste-
pOne Plus (Applied Biosystems). Data were normalized by the level of 18S
expression in each individual sample. 2-DDCt method was used to calculate
relative expression changes.ISUPPLEMENTAL INFORMATION
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